Akari Therapeutics, Plc (NasdaqCM: AKTX)
Health Care · Biotechnology · US
$8.18
-6.73% today · -73.4% 1Y
Akari Therapeutics, Plc (NasdaqCM: AKTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $18.69M and employs 6 people.
Over the last twelve months the share price has lost 73.4%, trading between 3.02 and 33.60.
Tweenvest scores Akari Therapeutics, Plc across four factors: quality 33/100, value 41/100. Its strongest factor is value.
AKTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $18.69M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -23.94
- Dividend yield
- —
- Beta (5Y)
- 1.44
- 52-week high
- $33.60
- 52-week low
- $3.02
- Avg volume (3M)
- —
- Shares outstanding
- 2.29M
- Employees
- 6
- Next earnings
- —
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
- ISIN
- US00972G4055
- Listed since
- Jan 6, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Dextech Medical ABXSAT: DEX | $18.89M | Skr— | — |
| General Biologicals CorporationTPEX: 4117 | $18.79M | NT$8.61 | -8.31% |
| Quoin Pharmaceuticals, Ltd.NasdaqCM: QNRX | $18.74M | $3.90 | -13.33% |
| Estrella Immunopharma, Inc.NasdaqCM: ESLA | $18.70M | $0.43 | +4.88% |
| Kyntra Bio, Inc.NasdaqGS: KYNB | $18.55M | $4.58 | -12.26% |
| Defence Therapeutics Inc.CNSX: DTC | $18.22M | CA$0.34 | -15.00% |
| Neuphoria Therapeutics Inc.NasdaqGM: NEUP | $17.86M | $3.30 | -1.79% |
| CCME Global LimitedBSE: 514336 | $17.68M | Rs37.09 | +15.44% |
Figures last refreshed Oct 18, 2026.